A T-cell targeting vaccine composed of conserved epitopes may provide rapid, effective, and long-term immunity at sites of infection through the generation of tissue resident memory CD8+ T cells, as well as memory CD4+ T cells that support antibody responses. The gene discussed is CD8A; the disease is infection.